Alec Stranahan
Stock Analyst at Bank of America Securities
(3.98)
# 1,695
Out of 4,423 analysts
586
Total ratings
48.6%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintained: Sell | $34 | $63.96 | -46.84% | 22 | Jun 16, 2026 | |
| AGIO Agios Pharmaceuticals | Maintained: Buy | $40 | $34.16 | +17.10% | 31 | Jun 15, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Hold | $19 | $15.67 | +21.25% | 18 | Jun 15, 2026 | |
| AVTX Avalo Therapeutics | Initiated Coverage: Buy | $35 | $14.70 | +138.10% | 1 | Jun 12, 2026 | |
| CRBU Caribou Biosciences | Maintained: Buy | $6 | $1.64 | +265.85% | 15 | Jun 11, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $185 | $162.99 | +13.50% | 34 | Jun 8, 2026 | |
| ERAS Erasca | Maintained: Hold | $16 | $13.67 | +17.04% | 25 | Jun 8, 2026 | |
| TGTX TG Therapeutics | Maintained: Sell | $15 → $17 | $53.22 | -68.06% | 36 | Jun 4, 2026 | |
| CATX Perspective Therapeutics | Maintained: Hold | $6 | $2.95 | +103.39% | 17 | May 31, 2026 | |
| HCM HUTCHMED (China) | Maintained: Buy | $20 | $10.28 | +94.55% | 21 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $364 | $348.06 | +4.58% | 30 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 | $9.78 | +73.82% | 17 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 | $8.31 | +8.30% | 17 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $24.09 | +41.14% | 8 | May 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $9.16 | +74.67% | 20 | May 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $87 | $61.08 | +42.44% | 18 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $14 | $7.80 | +79.49% | 27 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 | $12.64 | +34.49% | 18 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 | $54.09 | +53.45% | 25 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $3.23 | +85.76% | 22 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $34.14 | +37.67% | 21 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.15 | +122.22% | 12 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $21 | $14.22 | +47.68% | 21 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $2.69 | - | 9 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $1.75 | - | 15 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 → $19 | $6.16 | +208.44% | 5 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $8 | $9.13 | -12.38% | 40 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.20 | -16.67% | 13 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $16 | $11.32 | +41.34% | 15 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $800 → $565 | $609.94 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,150 → $1,100 | $1,098.57 | n/a | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $21.23 | n/a | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $10 → $1 | $2.02 | n/a | 4 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $35 | $3.15 | n/a | 1 | Jan 15, 2021 |
Moderna
Jun 16, 2026
Maintained: Sell
Price Target: $34
Current: $63.96
Upside: -46.84%
Agios Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $34.16
Upside: +17.10%
Intellia Therapeutics
Jun 15, 2026
Maintained: Hold
Price Target: $19
Current: $15.67
Upside: +21.25%
Avalo Therapeutics
Jun 12, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $14.70
Upside: +138.10%
Caribou Biosciences
Jun 11, 2026
Maintained: Buy
Price Target: $6
Current: $1.64
Upside: +265.85%
Revolution Medicines
Jun 8, 2026
Maintained: Buy
Price Target: $185
Current: $162.99
Upside: +13.50%
Erasca
Jun 8, 2026
Maintained: Hold
Price Target: $16
Current: $13.67
Upside: +17.04%
TG Therapeutics
Jun 4, 2026
Maintained: Sell
Price Target: $15 → $17
Current: $53.22
Upside: -68.06%
Perspective Therapeutics
May 31, 2026
Maintained: Hold
Price Target: $6
Current: $2.95
Upside: +103.39%
HUTCHMED (China)
May 31, 2026
Maintained: Buy
Price Target: $20
Current: $10.28
Upside: +94.55%
May 31, 2026
Maintained: Buy
Price Target: $364
Current: $348.06
Upside: +4.58%
May 31, 2026
Maintained: Buy
Price Target: $17
Current: $9.78
Upside: +73.82%
May 31, 2026
Maintained: Hold
Price Target: $9
Current: $8.31
Upside: +8.30%
May 31, 2026
Maintained: Buy
Price Target: $34
Current: $24.09
Upside: +41.14%
May 29, 2026
Maintained: Buy
Price Target: $16
Current: $9.16
Upside: +74.67%
May 26, 2026
Maintained: Buy
Price Target: $83 → $87
Current: $61.08
Upside: +42.44%
May 14, 2026
Reiterated: Buy
Price Target: $25 → $14
Current: $7.80
Upside: +79.49%
May 13, 2026
Maintained: Hold
Price Target: $17
Current: $12.64
Upside: +34.49%
May 13, 2026
Maintained: Buy
Price Target: $83
Current: $54.09
Upside: +53.45%
May 13, 2026
Maintained: Hold
Price Target: $6
Current: $3.23
Upside: +85.76%
May 12, 2026
Reiterated: Buy
Price Target: $47
Current: $34.14
Upside: +37.67%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $3.15
Upside: +122.22%
May 8, 2026
Reiterated: Buy
Price Target: $24 → $21
Current: $14.22
Upside: +47.68%
May 7, 2026
Maintained: Sell
Price Target: n/a
Current: $2.69
Upside: -
Apr 30, 2026
Maintained: Sell
Price Target: n/a
Current: $1.75
Upside: -
Apr 28, 2026
Maintained: Buy
Price Target: $21 → $19
Current: $6.16
Upside: +208.44%
Apr 8, 2026
Reiterated: Sell
Price Target: $8
Current: $9.13
Upside: -12.38%
Mar 27, 2026
Reiterated: Sell
Price Target: $1
Current: $1.20
Upside: -16.67%
Mar 26, 2026
Reiterated: Buy
Price Target: $14 → $16
Current: $11.32
Upside: +41.34%
Dec 10, 2024
Initiated Coverage: Sell
Price Target: $800 → $565
Current: $609.94
Upside: n/a
Nov 1, 2024
Rated: Buy
Price Target: $1,150 → $1,100
Current: $1,098.57
Upside: n/a
Aug 15, 2023
Reiterated: Buy
Price Target: $6 → $5
Current: $21.23
Upside: n/a
Dec 2, 2022
Maintained: Sell
Price Target: $10 → $1
Current: $2.02
Upside: n/a
Jan 15, 2021
Downgraded: Hold
Price Target: $35
Current: $3.15
Upside: n/a